Biocon Beheer

Beheer criteriumcontroles 4/4

De CEO Biocon is Siddharth Mittal, benoemd in Dec2019, heeft een ambtstermijn van 4.92 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 57.31M, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.069% van de aandelen van het bedrijf, ter waarde ₹ 268.19M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 3 jaar.

Belangrijke informatie

Siddharth Mittal

Algemeen directeur

₹57.3m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	4.9yrs
Eigendom CEO	0.07%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	3yrs

Recente managementupdates

Recent updates

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

Nov 02

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Jun 29

Is Biocon (NSE:BIOCON) A Risky Investment?

Jun 11

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Jun 11

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

May 24

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

May 23

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Mar 20

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Feb 12

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Jan 23

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Jan 03

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Nov 13

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Aug 03

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Jul 03

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 02

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

May 26

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Mar 28

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Feb 26

Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate

Dec 17

Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?

Sep 05

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Jul 13

Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate

May 26

Analyse CEO-vergoeding

Hoe is Siddharth Mittal's beloning veranderd ten opzichte van Biocon's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹14b
Jun 30 2024	n/a	n/a	₹16b
Mar 31 2024	₹57m	₹57m	₹10b
Dec 31 2023	n/a	n/a	₹12b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹4b
Mar 31 2023	₹48m	₹48m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹6b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹42m	₹42m	₹6b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹43m	₹43m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹7b
Mar 31 2020	₹49m	₹31m	₹8b

Compensatie versus markt: De totale vergoeding ($USD 679.70K ) Siddharth } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 588.26K ).

Compensatie versus inkomsten: De vergoeding van Siddharth is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Siddharth Mittal (46 yo)

4.9yrs

Tenure

₹57,310,000

Compensatie

Mr. Siddharth Mittal, BCom, CA, CPA has been CEO and Director of Biocon Limited since December 1, 2019. He has been Managing Director of Biocon Limited since April 01, 2020 and served as its Joint Managing...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	46yrs	₹38.43m	40.49% ₹ 156.4b
Siddharth Mittal	MD, CEO & Director	4.9yrs	₹57.31m	0.069% ₹ 268.2m
Peter James Bains	Group Chief Executive Officer	1.2yrs	₹1.91m	geen gegevens
Mukesh Kamath	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Arun Gupta	Head of Operations	1.6yrs	geen gegevens	geen gegevens
Atanu Roy	Group Chief Information Officer	4.2yrs	geen gegevens	geen gegevens
Saurabh Paliwal	Head of Investor Relations	2.3yrs	geen gegevens	geen gegevens
Mayank Verma	Company Secretary & Compliance Officer	5.3yrs	₹5.75m	geen gegevens
Seema Ahuja	Global Head of Communications & Corporate Brand	no data	geen gegevens	geen gegevens
Maninder Puri	Head of Human Resources	no data	geen gegevens	geen gegevens
Paul Thomas	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Abhijit Zutshi	Commercial Head of Biocon Global Generics	no data	geen gegevens	0.019% ₹ 71.7m

2.3yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BIOCON wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kiran Mazumdar-Shaw	Founder & Executive Chairperson	46yrs	₹38.43m	40.49% ₹ 156.4b
Siddharth Mittal	MD, CEO & Director	4.9yrs	₹57.31m	0.069% ₹ 268.2m
Ravi Mazumdar	Non-Executive Non-Independent Director	24.3yrs	₹6.23m	0.44% ₹ 1.7b
Bobby Parikh	Independent Non-Executive Director	6.3yrs	₹7.81m	geen gegevens
Naina Lal Kidwai	Additional Non-Executive Independent Director	2.6yrs	₹6.24m	geen gegevens
Satish Garg	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nicholas Haggar	Independent Director	less than a year	₹5.20m	geen gegevens
Shashank Joshi	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rekha Menon	Independent Director	1.3yrs	₹5.70m	geen gegevens
Eric Mazumdar	Non-Executive Director	3yrs	₹5.57m	0.27% ₹ 1.0b
John Petrie	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Atul Dhawan	Non-Executive and Independent Director	less than a year	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BIOCON wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Biocon Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Biocon Limited, Annual General Meeting, Aug 09, 2024

Insider recently sold ₹5.3m worth of stock

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Recent updates

Consensus EPS estimates fall by 20%

Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results

New major risk - Financial position

Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E

Second quarter 2025 earnings released: ₹0.13 loss per share (vs ₹1.05 profit in 2Q 2024)

Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?

Biocon Limited to Report Q2, 2025 Results on Oct 30, 2024

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

High number of new directors

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited to Report Q1, 2025 Results on Aug 08, 2024

Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors

Upcoming dividend of ₹0.50 per share

Biocon Limited Announces Appointment of Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer

Investor sentiment improves as stock rises 18%

Is Biocon (NSE:BIOCON) A Risky Investment?

Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50

Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations

Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50

New minor risk - Earnings quality

Dividend of ₹0.50 announced

Biocon Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹5.3m worth of stock

Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?

Biocon Limited Accepts Resignation of Indranil Sen as Chief Financial Officer

Insider recently sold ₹3.3m worth of stock

Insider recently sold ₹1.1m worth of stock

Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next

Biocon Limited Announces Nehal Vora Resigns as Commercial Head, Effective March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price

Investor sentiment improves as stock rises 17%

Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price

Insider recently sold ₹1.8m worth of stock

Biocon Limited Announces the Resignation of Prasad Deshpande as Head SCM and Central Engineering, Senior Management Personnel, Effective January 16, 2024

Biocon Limited Appoints Nicholas Robert Haggar as an Independent Director

These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Biocon Limited Announces Management Changes

Insider recently sold ₹13m worth of stock

Group Chief Information Officer recently sold ₹3.2m worth of stock

Biocon Limited Appoints Peter Bains as Biocon Group Chief Executive Officer

Insider recently sold ₹1.6m worth of stock

Consensus EPS estimates fall by 16%

Biocon Limited Approves Appointment of Ms. Rekha Mehrotra Menon as an Independent Director

Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)

Biocon Limited Announces Cessation of Vijay Kumar Kuchroo as a Director

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Insider selling

Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50

Is Biocon (NSE:BIOCON) Using Too Much Debt?

Upcoming dividend of ₹1.50 per share at 0.6% yield

Insider recently sold ₹5.3m worth of stock

Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50

Biocon Limited, Annual General Meeting, Aug 11, 2023

Biocon Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 8, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase by 12%

Insider recently sold ₹2.3m worth of stock

Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)

Insider recently sold ₹1.1m worth of stock

Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 17%

Price target decreased by 7.4% to ₹316

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt

Third quarter 2023 earnings released: ₹0.35 loss per share (vs ₹1.57 profit in 3Q 2022)

Biocon Limited to Report Q2, 2024 Results on Nov 06, 2023

Consensus forecasts updated